We at Ferrer are focused on identifying projects whose value makes a difference
Ferrer’s R&D activity aims to respond to medical needs that are not covered by providing innovative solutions. Our pipeline includes projects of differentiated therapeutic value in three strategic areas, namely the central nervous system, pain/cardiometabolism and rare diseases/oncological support therapies. Our portfolio combines disruptive innovation approaches (such as advanced therapies) and incremental type innovations (like the development of value added medicines (VAMs).
Digital Health and Technology
This is the department that drives digital health innovation, the rallying point between technology, health and healthcare provision and living as part of a society. Digital health is centred around building more customised, precise treatments to achieve better clinical results, enriching the experience of patients, healthcare professionals and carers alike while increasing the efficiency and sustainability of healthcare systems to make them more accessible and integrated.
We use the Ferrer 4 Future programme to challenge the entrepreneurial ecosystem, collaborating with technology companies to resolve the challenges set. Technological solutions offered by start-ups include hardware, like medical devices, and software combined with medication, like cognitive assistants to manage an ailment, but the solution could even come in the form of software that acts as a treatment in and of itself, without the intervention of any medication, in which case, we refer to it as digital therapy.
A Ferrer company based in Palo Alto, California (USA) who owns the Staccato® platform for the administration of active ingredients via the lungs, allowing for kinetics that are similar to those achieved intravenously, but by means of a non-invasive route. Alexza’s projects generate clinical responses just a few minutes after the inhaled administration of the medication, and are oriented towards acute symptomatic treatment of central nervous system pathologies. The use of the platform is available for collaboration with third parties wishing to test their molecules on it. Similarly, Alexza has a portfolio of in-house projects being developed that include a Staccato platform for known compounds available by means of another delivery route.
For more information on Alexza, please visit alexza.com
This is how the Staccato® system works
The Staccato device contains a quick heating system capable of reaching very high temperatures to sublimate the unformulated active ingredient which is deposited as a thin film over a stainless steel substrate. The substrate surface instantaneously heats to create a condensation aerosol the moment the patient draws a breath through the Staccato system. The patient inhales particles of active ingredient whose size allows for reaching deeper, more vascularised areas of the lung. This allows for rapid, complete absorption to the bloodstream.